

Modeling Complex Particle Interactions in Dry Powder Inhaler

Xiaoyu Liu¹, Mostafa Sulaiman¹, Jari Kolehmainen¹ Ali Ozel² and Sankaran Sundaresan¹ ¹ Princeton University, ² Heriot Watt university


> Session: Particle Technology Forum (03) Particle Technology in Product Design Nov 20, 2020



Overview




- Dry power inhalers (DPI) deliver active pharmaceutical ingredients (API) to human airways and lungs
- API particles are small (<5 μ m), cohesive and hard to fluidize
- Larger lactose particles (70 μ m ~ 100 μ m) are used as carrier
- Inhalation fluidizes powder and releases API fragments
- Fragments smaller than 5 μ m are delivered to lungs



Fine Particle Fraction



• The amount of drug delivered depends on the fraction of API released, characterized by Fine Particle Fraction (FPF)







Modeling Complex Particle Interactions in Dry Powder Inhaler Based Drug Delivery




Project objectives

- Assemble a simulation platform to follow the transport of carrier and api particles (Accomplished ✓)
- Explore how inter-particle forces affect release fractions through agglomerate wall collisions and DPI simulations (Current talk)
- Validate the code and use it to assess effect of DPI device geometry on RF and FPF (Mostafa Sulaiman's talk – same session)


Methodology: CFD-DEM







Туре	Diameter	Number	Vol %
API	5µm	130	4.5
Carrier	70µm	1	95.5



An agglomerate is formed with either

- Van der Waals cohesion (Hamaker model)
- or electrostatic interaction (assigning opposite charges to carrier and API)


Collide the agglomerate with a wall and analyze FPF and release fraction

10 different initial configurations

[3] Nguyen et al., Int J Pharmaceut, 57, 31 (2018)[4] van Wachem, et al. AIChE Journal 63.2 (2017): 501-516.

6

Screen-haler simulation




Coarsening Approach: representative particle




Particle-based coarsening approach:

 Model API particles by "representative particles", each representing N primary API particles (N is the coarsening factor)



$$N_i m_i \frac{d\boldsymbol{v}_i}{dt} = \max(N_i, N_j) f_{ij}(\boldsymbol{x}_i, \boldsymbol{x}_j) + N_i f_i^d$$


 N_i, N_j : numbers of primary particles in representative particle *i* and *j* respectively f_{ij} : interaction force between two primary particles *i* and *j* f_i^d : drag force experienced by one primary particle *i*



Coarsening correction




9



Cohesion among API particles constitutes an additional attractive force between carrier and API.

=> This effect can be corrected to ensure consistent results in coarsened cases

These corrections can be tuned using short agglomeratewall collision test.




Coarsening Factor

The ratio of modified Hamaker constant Ha_M to original Hamaker constant Ha_0 for different coarsening factors

Screen-haler simulation results



	Coarsening Factors			
	1	3	5	
FPF	0.585	0.594	0.560	
Release	0.751	0.709	0.691	




Nature of particle interaction




Van der Waals' cohesion

(always attractive)



Electrostatic interaction (attractive between API and carrier, repulsive among API)



Binary systems of particles tend to pick up opposite charges


API particles may cluster on the carrier surface

API particles maximize separation with other API particles due to repulsion

Different agglomerate configurations between VDW cohesion and electrostatic interaction

Agglomerate-wall collision





Summary



- We have developed a CFD-DEM code for simulating dry powder inhaler
- We formulated a representative particle approach that saves computational cost and implemented correction to ensure consistent result
- As VDW cohesion and electrostatic interaction increases, fewer API get released.
 - VDW cohesion: some API may be released as APIagglomerate
 - Electrostatic interaction: all API are released as singlet

Acknowledgement



FDA U.S. FOOD & DRUG